Previous 10 | Next 10 |
2024-05-06 10:34:16 ET More on Esperion Therapeutics A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups Esperion stock jumps 18% in wake of F...
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website . JMP Securities’ Life Sc...
2024-04-25 10:05:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0% since inception, compa...
ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial ...
2024-04-08 06:16:08 ET Esperion Therapeutics ( NASDAQ: ESPR ) shares gained 7% premarket on Monday after the company touted clinical benefits of NEXLETOL (bempedoic acid) tablets in diverse populations, including women, Hispanic/Latinx, and patients with obesity.... ...
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With...
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration’s (FDA) re...
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23 rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET. The Esper...
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen) Outcomes subgroup analyses as poster presentations a...
2024-03-25 11:50:24 ET More on Esperion Therapeutics A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript Esperion Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Pres...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...